Navigation Links
SGX Pharmaceuticals Announces First Quarter Financial Results and Gives Pipeline Update
Date:5/13/2008

$0.21 $(0.03) $0.18 $(0.01) $(0.06) $(0.07)

Diluted net income

(loss) per common

share: $0.21 $(0.03) $0.18 $(0.01) $(0.06) $(0.07)

Research and

development

expenses $11,055 $294 $11,349 $9,517 $501 $10,018

General and

administrative

expenses $1,789 $332 $2,121 $1,745 $488 $2,233

SGX PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

March 31, December 31,

2008 2007

Assets

Cash, cash equivalents and short-term

investments $30,867 $38,990

Accounts receivable 1,645 2,706

Other current assets 1,847 1,187

Property and equipment, net 3,842 3,889

Other assets 4,285 4,284

Total assets $42,486 $51,056

Liabilities and stockholder's equity

Current liabilities $12,190 $24,991

Deferred revenue, long-term 904 1,042

Other liabilities, net of current portion - -

Stockholder's equity 29,392 25,023

Total liabilities and stockholder's equity $42,486 $51,056

1) In addition to disclosing financial results calculated in accordance

with generally accepted accounting principles (GAAP), this table

contains non-GAAP financial measures that
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , ... September 01, 2015 , ... ... joint disease. , Equine cervical facet joint problems can be caused by ... and can cause impingement of nerve roots or of the spinal cord itself. ...
(Date:9/1/2015)... ... 2015 , ... Leading CEOs, CSOs, CMOs, and heads of ... prominent academics and key investors for Neuro Advance Boston, October 14, 2015 at ... , Neuro Advance Boston focuses on the latest developments and opportunities in neuroscience ...
(Date:9/1/2015)... Sept. 1, 2015   Medfusion, Inc., ... relationship between doctors and patients, today announced a ... N.C. -based venture capital firms.   ... association with Bull City Venture Partners and Hatteras ... Founder and Executive Chairman. "Both firms, experience working ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new host-based ... researchers at the Keck Graduate Institute and its collaborators. The discovery has the ... were published online on August 27 by Scientific Reports, an open access research ...
Breaking Biology Technology:VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4
...   Synthetic Biologics, Inc. (NYSE Amex: SYN ), ... medicines for serious illnesses, announced today that to improve ... split the roles of Chairman and Chief Executive Officer, ... independent, non-executive Chairman of the Board. Mr. Kraws has ...
... 10, 2012   GeneLink, Inc. (OTC Bulletin ... biotech company, reports financial results for the fiscal year ended ... , The Company reached an agreement in October 2011 ... to Capsalus Corp (OTCBB:WELL.OB, or "Capsalus"). Capsalus assumed management of ...
... Laboratory has entered into a contractual agreement for ancillary ... Network and their 8.6 million lives network. ... pioneer of claims optimization, Stratose (formerly operating as Coalition ... KeyClaims) works to reduce the cost and ensure the ...
Cached Biology Technology:Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman 2Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman 3GeneLink Reports 2011 Financial Results 2GeneLink Reports 2011 Financial Results 3Aviir Laboratories Announce National Agreement with Stratose 2Aviir Laboratories Announce National Agreement with Stratose 3
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Saudi Arabia Biomedical Sensors Market - Growth, ... The Saudi Arabia Biomedical Sensors market ... CAGR of 3.64% over the period 2014-2020 ... adaptable to the genetic formulation of each individual. These ...
(Date:8/24/2015)... Aug. 24, 2015  Based on its recent analysis of ... the 2015 African Biometrics Company of the Year Award. DERMALOG ... commercial success in Africa . It has ... it has implemented one of the largest biometric mass applications ... as the Central Bank of Nigeria ...
(Date:8/18/2015)... 2015  Navitas today announced that it ... Submission Content Management webinar scheduled on August ... to the Implementation of Regulatory Submission Standards ... industry, vendors, health authorities, consultants and the ... a standard method of implementing electronic submission ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
... Duke University Medical Center and Laboratory Corporation of ... formation of a joint venture to commercialize new ... the translation of newly discovered biomarkers into widely ... responses, predict disease progression, and evaluate any number ...
... NASA,s Aqua and Terra satellites fly around the ... land changes. Over the last three days these satellites ... plume from the Eyjafjallajkull volcano in Iceland. Eyjafjallajkull ... spewing ash into the atmosphere. Volcanic eruptions are important ...
... 2010 Scientists from The Scripps Research Institute have provided ... mutations lead to Type 1 diabetes. This new molecular understanding ... other autoimmune diseases. The study was published in an ... on April 19, 2010, and will appear in the ...
Cached Biology News:Duke, LabCorp combine forces to create the Biomarker Factory 22 NASA Satellites Capture Last 3 Days of Eyjafjallajokull's Ash Plume 2Scripps Research scientists reveal how genetic mutations may cause type 1 diabetes 2Scripps Research scientists reveal how genetic mutations may cause type 1 diabetes 3
Mouse polyclonal antibody to REXO4 - XPMC2 prevents mitotic catastrophe 2 homolog (Xenopus laevis)...
... The Corning CellBIND surface is produced by ... more hydrophilic surface giving more consistent, even ... CellBIND enhances cell attachment and growth uunder ... medium. • CellBIND may provide a more ...
... 20 Plasma Immunodepletion Kit specifically removes 20 ... plasma or serum in preparation for further ... into the plasma proteome whether you use ... chromatography or go straight to mass spectrometry. ...
... a direct antibiotic-based selection ... Recombinant selection depends solely ... the need for costly ... and inexpensive process provides ...
Biology Products: